Day One Biopharmaceuticals, Inc. (DAWN)
$21.53+0.00%Close
BUYBULL · day 37
Key stats
- Market cap
- $2.2B
- Beta
- -1.75
- P/E (TTM)
- -31.20
- 1W
- +0.28%
- 1M
- +0.75%
- vs SPY 1W
- -0.88%
- vs SPY 1M
- -2.24%
Industry peers
FMP comparable companies · ranked by market cap
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 4$16.03+3.69%
- VIRBUYVir Biotechnology, Inc.$2.0BBULLQ 13$11.70+5.22%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.94-0.15%
- REPLSELLReplimune Group, Inc.$1.1BRECOVERYQ 14$13.42+2.91%
- GERNSELLGeron Corporation$786MRECOVERYQ 11$1.23+0.82%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -5$16.73+0.12%
- ATXSAstria Therapeutics, Inc.$718M$12.58
- VALNSELLValneva SE$548MCRISISQ -0$5.78+1.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on DAWN?
- LOPJLB’s latest quantitative signal on Day One Biopharmaceuticals, Inc. (DAWN) is BUY in a BULL regime. Signals are updated daily.
- What market regime is DAWN in?
- Day One Biopharmaceuticals, Inc. (DAWN) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Day One Biopharmaceuticals, Inc. (DAWN) do?
- Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for yo…